Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18546081 | MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 | Non-Final OA | The Regents of the University of California |
| 18274069 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB8 INTEGRIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18094176 | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc |
| 17209160 | MATERIALS AND METHODS FOR TREATING CANCER | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18249241 | COMPOSITIONS AND METHODS FOR MUC18 TARGETING | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18886988 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | Final Rejection | Iovance Biotherapeutics, Inc. |
| 18124717 | SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY | Final Rejection | BIOND BIOLOGICS LTD. |
| 17914855 | IMMUNE ACTIVATING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18190199 | PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | BGI SHENZHEN |
| 17586067 | METHODS OF USE FOR CAR T CELLS | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18261376 | ANTI-CD38 ANTIBODIES AND THEIR USES | Non-Final OA | MORPHOSYS AG |
| 18253493 | ANTI-CD25 ANTIBODIES | Non-Final OA | UNIVERSITE PARIS EST CRETEIL VAL DE MARNE |
| 18019871 | Combined Preparation | Final Rejection | MEDRx Co., Ltd. |
| 17251425 | METHODS FOR PREDICTING RESPONSIVENESS OF LUNG CANCER PATIENTS TO HER2-TARGETING THERAPIES | Final Rejection | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18137279 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF CARCINOMA | Non-Final OA | Isofol Medical AB |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 18028698 | FIBRONECTIN EXTRA DOMAIN B (EDB) -SPECIFIC CAR-T FOR CANCER | Non-Final OA | JIANGSU CELL TECH MEDICAL RESEARCH INSTITUTE CO., LTD. |
| 18245222 | COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER | Non-Final OA | Jaqueline WILLEMANN ROGERIO |
| 18041195 | CHIMERIC TIM RECEPTORS AND USES THEREOF | Final Rejection | CERO THERAPEUTICS HOLDINGS, INC. |
| 17997025 | ANTIBODY BINDING WITH SPECIFIC EPITOPE IN HUMAN IL-4R ALPHA AND APPLICATIONS OF ANTIBODY | Non-Final OA | CONNECT BIOPHARMA HONGKONG LIMITED |
| 17996022 | Anti-IL13R-alpha2 Antibodies, Antigen-Binding Fragments and Uses Thereof | Non-Final OA | ELICERA THERAPEUTICS AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy